Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.56 |
| ▸ | NAMPT | P43490 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20382371 | 0.88 | TBXAS1 (0.68) | CYP3A4TBXAS1MAPT | |
| SCHEMBL12561403 | 0.84 | CYP3A4 (0.67) | CYP1A2CYP3A4CYP2C9CYP2C19TBXAS1 | |
| SCHEMBL26333386 | 0.83 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2C9CYP2C19TBXAS1 | |
| SCHEMBL9579600 | 0.83 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2C9CYP2C19TBXAS1 | |
| SCHEMBL7807329 | 0.83 | CYP3A4 (0.71) | CYP1A2CYP3A4CYP2C9CYP2C19TBXAS1 | |
| SCHEMBL12251221 | 0.83 | MKNK1 (0.58) | CYP1A2CYP3A4CYP2C9CYP2C19TBXAS1 | |
| SCHEMBL2568441 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL12376674 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19TBXAS1 | |
| SCHEMBL21890782 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19TBXAS1 | |
| SCHEMBL9579396 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | CYP1A2 486/4885CYP3A4 2583/4885CYP2C9 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.